NutriCare vs NutriTool: Critical appraisal of Ph III randomized trial
249 pts with newly diagnosed stage I–IV lung cancer recruited across 4 cancer centres
Does Active Nutritional care makeany difference?
Complete NutriCare package is not superior to nutrition education alone
IMPT vs IMRT in oropharyngeal cancer
DOI: 10.1016/j.esmoop.2026.108602. S
Intensity-modulated proton therapy (IMPT) reduces acute severe toxicity compared with intensity-modulated photon radiotherapy (IMRT) but this analysis does not establish superior tumour control or survival
Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0
DOI: 10.1200/JCO-26-02462
Summary of All Recommendations:
Biomarker Testing
First-line therapy for patients with
pMMR/MSS & dMMR/MSI-H Advanced
BTC
2nd Line Rx with/without Targeted Rx
Does adding periop pembrolizumab to neoadjuvant gemcitabine–cisplatin, followed by radical cystectomy and adjuvant pembrolizumab, improve outcomes in cisplatin-eligible muscle-invasive bladder cancer (MIBC)?
KEYNOTE-866 trial @ ESMO 2026
N=907
Median FU 5y
EFS HR 0.88 p=0.13
JCOG2110 / OLIGAMI Ph III
Question: Does adding definitive metastasis-directed therapy (MDT) to subtype-specific systemic therapy improve survival in oligometastatic breast cancer?
SABR-COMET: OS benefit, but had only 18/99 Breast Ca pts
NRG BROO2 =129 All breast -ve study
ConCERT Trial Ph III randomized noninferiority trial comparing weekly cisplatin with q3w during definitive RT for locally advanced head and neck SCC.
Cisplatin 40 mg/m² weekly Vs Cisplatin 100 mg/m² q3w
N=278
Primary End Point
2yLR 61.3% Vs 51.1% (+10.2%)
Gr3 Toxicity worse 3w
Every-other-week GEMDOC in heavily pretreated mCRPC
DOI: 10.1016/j.clgc.2026.102657.
N=34 heavily pretreated mCRPC
GEM DOC
Gemcitabine: 1,500 mg/m² IV
Docetaxel: 50 mg/m² IV
Given on days 1 and 15 of a 28-day cycle.
Median PFS =4.17m
Median OS = 11.6m
Neoadjuvant Surgical Enablement in Renal Cell Carcinoma (RCC)
Doi;10.1016/j.clgc.2026.102688
34 studies
Post NAC Rx
80% partial nephrectomy achievement
32% ORR
44% venous tumour thrombus downstaging
28% grade≥3 treatment-related adverse event
13% major Postop Complication
HypoMast-IMNI Trial (2026):PhIII
Can hypofractionated PMRT delivered in 16 #, replace conventional 25# PMRT without compromising locoregional control when internal mammary node irradiation (IMNI) is required?
N=1494
42.56 Gy in 16 # was noninferior to 50 Gy in 25 #
Addition of irinotecan to CTRT as preoperative treatment for locally advanced rectal cancer (ARISTOTLE Trial)
DOI: 10.1016/S1470-2045(26)00132-4
75 UK centres=564 pts
MRI-defined high-risk rectal cancers
Adding concurrent irinotecan did not improve DFS, but added Toxicity
Antibody–drug conjugates in breast cancer — first-line and curative settings
Current Opinion in Oncology. 2026;38:441–448.
DOI:10.1097/CCO.0000000000001265
PD-1/PD-L1 inhibitors combined with SRS for brain metastases: Critical appraisal
Systematic review and meta-analysis · Published 17 October 2026 · Volume 43, Article 58
34 studies (2016-2025)
2587 Brain mets
Hypothesis and Feasibility testing
Not for Clinics yet
Decoding Hereditary Breast & ovarian Cancer
Conglomerates all evidence over last 5 years
High intensity summary
Identify patients
Estimate incidences
Decide Testing
Managing = Risk Reducing Sx Vs Chemoprevention Vs Surveillance
Metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), specifically SFPQ::TFE3 fusion-positive RCC.
My first ever diagnosis on this entity
Where Pathologist IHC
+CGP comprehensive analysis
Helped clinch this entity
Clinical Snapshot:
Problem was
Neither IHC could tell u source of origin
Nor CGP tells u what origin is this..it tells u about Fusion which has no target therapy.
Only when u go in depth of this fusion
this special distinct entity emerges
Which is district molecular entity
Path CR and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
DOI: 10.1016/S0140-6736(13)62422-8
Does achieving a pCR after neoadjuvant systemic therapy reliably predict improved long-term survival?
12 trials,11955 pts @5.4y IPD
Answer = No
It does nt
Adverse effects of immune-checkpoint inhibitors
Nature Reviews Clinical Oncology. 2019;16:563–580. DOI: 10.1038/s41571-019-0218-0.
Early recognition, prompt treatment and multidisciplinary management are essential to reducing severe toxicity and treatment-related deaths.
